https://www.sciencedirect.com/science/article/pii/S10838791193044...

https://www.sciencedirect.com/science/article/pii/S1083879119304495#:~:text=Steroid%2Drefractory%20aGVHD%20was%20defined,after%20completion%20of%20steroid%20taper.


https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2012.09129.x


https://journals.sagepub.com/doi/full/10.1177/2040620713489842


Adding "All enrolled subjects in this trial must receive corticosteroids at a minimum dose of oral prednisone 2 mg/kg/day (or methylprednisolone 1.6 mg/kg/day IV) as therapy for aGvHD for at least for 72 hours post enrollment" is in my opinion CYP's approach to standardise the P2 trial and is in line with current first-line therapies for newly diagnosed patients with high-risk aGvHD.


The above is also in line with other clinical trials (past and present) for newly diagnosed patients with high-risk aGvHD:


https://www.sciencedirect.com/science/article/pii/S1083879109001530


https://clinicaltrials.gov/ct2/show/NCT04397367


https://clinicaltrials.gov/ct2/show/NCT01002742


The desperation displayed by the lack of any meaningful content, cock-eyed-"IMHO"-conclusions - in attempts to discredit a stock that is currently valued at a MC of just over A$42 million - by investors of MSB is well received by the way. Especially the frequency of these poor attempts show how much CYP is on your minds, despite our current SP of A$0.29. I take that as a compliment and for that I thank you.